Newsroom

2019

---

• Immunotec’s ‘Unlimited’ Conference in Mexico City Shatters Attendance Record
  (March 8, 2019)

2018

---

• 4,000 people attend Immunotec’s grand opening in Bogotá, Colombia
  (October 17, 2018)
• Immunotec recognized in Direct Selling News April edition: A year of unprecedented growth and success
  (April 16, 2018)

2017

---

• Network marketing professional, Meredith Berkich, joins Immunotec as President of its U.S. business
  (December 1, 2017)
• Immunotec announces completion of arrangement
  (May 18, 2017)
• Immunotec announces receipt of final order for arrangement
  (May 12, 2017)
• Immunotec shareholders approve arrangement with 1111267 B.C. LTD.
  (May 11, 2017)
• Immunotec announces new director and reports on AGM results
  (April 27, 2017)
• Immunotec files management proxy circular
  (April 19, 2017)
• Q1-2017 - Period Ended January 31, 2017
  (March 27, 2017)
• Immunotec enters into agreement to be acquired
  (March 22, 2017)
• Immunotec provides an update on taxation matters in Mexico
  (March 21, 2017)
• Immunotec reports record-breaking Convention attendance for its "brand evolution" launch
  (February 16, 2017)
• Q4-2016 - Year Ended October 31, 2016
  (January 26, 2017)

2016

---

• Q3-2016 - Period Ended July 31, 2016
  (September 16, 2016)
• Q2-2016 - Period Ended April 30, 2016
  (June 16, 2016)
• Artemis Racing to work with Immunotec
  (May 19, 2016)
• Immunotec announces the nomination of Mario Paradis to its Board of Directors and reports AGM results
  (April 28, 2016)
• Immunotec renews material contract with Glanbia Nutritionals
  (April 8, 2016)
• Q1-2016 - Period Ended January 31, 2016
  (March 30, 2016)
• Immunotec announces executive promotions
  (February 29, 2016)
• Immunocal^® and Immunocal Platinum^® certified by international testing company LGC
  (February 25, 2016)
• Immunotec hosted record attendance at their 20^th anniversary conventions
  (February 24, 2016)
• Immunotec expands product offering with new skin care collection
  (February 24, 2016)
• Q4-2015 - Year Ended October 31, 2015
  (January 28, 2016)

2015

---

• Immunotec Reports Issuance of Options
  (September 22, 2015)
• Q3-2015 - Period Ended July 31, 2015
  (September 17, 2015)
• Immunotec Resolves Taxation Matters in Mexico
  (July 21, 2015)
• Immunotec Obtains $2,780,000 of New Financing
  (July 20, 2015)
• Immunotec Reports Issuance of Options
  (June 17, 2015)
• Q2-2015 - Period Ended April 30, 2015
  (June 12, 2015)
• Immunocal^® First to be Granted Strength and Performance Claim for a Stand-Alone Whey Protein by Health Canada
  (May 12, 2015)
• Immunotec Ranks No. 97 in Sixth Annual DSN Global 100
  (April 20, 2015)
• Q1-2015 - Period Ended January 31, 2015
  (March 17, 2015)
• Q4-2014 - Year Ended October 31, 2014
  (January 26, 2015)

2014

---

• New Study Demonstrates Immunocal^® Supplementation Increases Muscle Strength in Elderly Adults
  (November 27, 2014)
• Immunotec Celebrates a Fourth Anniversary in Mexico and Announces the Appointment of a New Director
  (October 30, 2014)
• Immunotec Opens New Sales Office in Commerce, California, U.S.A.
  (October 21, 2014)
• Immunocal^® used in novel Prehabilitation Study
  (October 14, 2014)
• Q3-2014 - Period Ended July 31, 2014
  (September 29, 2014)
• Immunotec launches The Immunotec Children's Fund at their 2014 Annual BBQ Event
  (September 19, 2014)
• Immunotec to Appeal Recent Court Decision in Mexico
  (September 15, 2014)
• Immunotec Files a Preliminary Short form Prospectus
  (July 3, 2014)
• Rowing Canada Aviron and Immunotec Inc. Announce Winning Clubs for Visit from National Team Members
  (June 11, 2014)
• Q2-2014 - Period Ended April 30, 2014
  (May 29, 2014)
• Q1-2014 - Period Ended January 31, 2014
  (March 27, 2014)
• Immunotec Announces Change in Marketing Management
  (March 6, 2014)
• Immunotec Announces Completion of its International Convention in Mexico City
  (February 25, 2014)
• Q4-2013 - Year Ended October 31, 2013
  (February 13, 2014)

2013

---

• Immunotec named an official sponsor of Rowing Canada Aviron
  (December 3, 2013)
• Immunotec Announces Agreement
  (November 4, 2013)
• Q3-2013 - Period Ended July 31, 2013
  (September 12, 2013)
• Immunotec Announces a Corporate Update
  (June 14, 2013)
• Q2-2013 - Period Ended April 30, 2013
  (June 14, 2013)
• Immunotec Announces Recent Claim
  (May 29, 2013)
• Immunotec Announces New CEO
  (May 17, 2013)
• Immunotec Announces CEO Departure
  (May 13, 2013)
• Immunotec Announces Normal Course Issuer Bid
  (May 2, 2013)
• Q1-2013 - Period Ended January 31, 2013
  (March 21, 2013)
• Immunotec Announces Grant of Options
  (February 12, 2013)
• Q4-2012 - Year Ended October 31, 2012
  (February 7, 2013)

2012

---

• Q3-2012 - Period Ended July 31, 2012
  (September 17, 2012)
• Q2-2012 - Period Ended April 30, 2012
  (June 15, 2012)
• Proposed Share Consolidation
  (February 20, 2012)
• Q4-2011 - Year Ended October 31, 2011
  (February 20, 2012)

2011

---

• Immunotec mourns the death of Dr. Gustavo Bounous
  (December 29, 2011)
• Immunotec Announces closing $3.45M of New Financing
  (September 15, 2011)
• Q3-2011 - Period Ended July 31, 2011 and Changes to Board of Directors
  (September 9, 2011)
• Immunotec Appoints Mr. Daniel Audet as Vice-President of Marketing
  (August 3, 2011)
• Immunotec and Nova Southeastern University (NSU) Collaborate on New Autism Study using Immunocal^®
  (July 13, 2011)
• Q2-2011 - Period Ended April 30, 2011
  (June 17, 2011)
• Important New Research using Immunocal^® Shows Promise in Lou Gehrig’s Disease
  (June 13, 2011)
• Immunotec Signs Material Contract with Glanbia Nutritionals
  (May 24, 2011)
• NSU and Immunotec Start Clinical Trail in Autism
  (March 30, 2011)
• Q1-2011 - Period Ended January 31, 2011
  (March 25, 2011)
• Q4-2010 - Year Ended October 31, 2010
  (February 21, 2011)
• Immunotec Welcomes New President
  (January 24, 2011)

2010

---

• Immunotec mourns passing of Senior VP - Dr. Wulf Dröge, Ph.D.
  (December 22, 2010)
• Immunotec CEO to retire at the end of the year
  (December 9, 2010)
• Immunotec announces Stock Option Grant
  (November 12, 2010)
• Q3-2010 - Period Ended July 31, 2010
  (September 17, 2010)
• Immunotec announces changes to Management
  (September 7, 2010)
• Immunotec appoints new Executive Chairman of the Board
  (August 24, 2010)
• Immunotec mourns passing of Chairman Alex Konigsberg
  (August 10, 2010)
• Q2-2010 - Period Ended April 30, 2010
  (June 21, 2010)
• Immunotec to Present at the World Cancer Congress Conference In Singapore
  (June 16, 2010)
• Immunotec Announces Closing of Previously Announced Transaction
  (May 13, 2010)
• Immunotec Acquires Assets from Licensee in Mexico and Expands its Seamless Network
  (May 3, 2010)
• Immunotec Appoints Robert M. Henry as New Director
  (May 3, 2010)
• Q1-2010 - Period Ended January 31, 2010
  (March 26, 2010)
• Q4-2009 - Year Ended October 31, 2009
  (February 17, 2010)

2009

---

• Immunotec Announces commencement of IMN 1207 US Lung Cancer Study funded by Moffitt Cancer Center CCOP Research Base
  (December 7, 2009)
• Immunotec appoints Patrick Montpetit as Chief Financial Officer
  (October 1, 2009)
• Q3-2009 - Period Ended July 31, 2009
  (September 29, 2009)
• Immunotec Announces an Independent, Clinical Research Initiative at Beaumont Hospital’s Community Clinical Oncology Program (CCOP)
  (August 3, 2009)
• Immunotec Inc. announces the closing of its Korean operations
  (July 31, 2009)
• IMMUNOTEC announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process.
  (July 6, 2009)
• Q2-2009 - Period Ended April 30, 2009
  (June 23, 2009)
• Election of New Director
  (March 30, 2009)
• Q1-2009 - Period Ended January 31, 2009
  (March 25, 2009)
• Q4-2008 - Year Ended October 31, 2008
  (February 12, 2009)

2008

---

• Immunotec congratulates 2008 Nobel Prize Winner in Medicine, Dr. Luc Montagnier
  (October 23, 2008)
• Q3-2008 - Period Ended July 31, 2008
  (September 24, 2008)
• Oral Tolerability of Cysteine-Rich Protein Isolate (Immunocal^®) in Autism – A Pilot Study
  (August 28, 2008)
• Immunotec Inc. Announces New Chief Operating Officer
  (July 3, 2008)
• Q2-2008 - Period Ended April 30, 2008
  (June 19, 2008)
• Testing Shows Athletes Can Safely Benefit from Immunocal^®
  (April 18, 2008)
• Q1-2008 - Period Ended January 31, 2008
  (March 28, 2008)
• Q4-2007 - Year Ended October 31, 2007
  (February 19, 2008)
• Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients: A Promising Intervention Study
  (January 17, 2008)

2007

---

• Health Canada approves health claim for Immunocal^®
  (November 13, 2007)
• Immunotec Inc. announces appointment of President and CEO James A. Northrop
  (October 11, 2007)
• Q3-2007 - Period Ended July 31, 2007
  (September 27, 2007)
• Immunotec Inc. announces retirement of President and CEO C.H. (Chuck) Roberts
  (September 26, 2007)
• Q2-2007 - Period Ended April 30, 2007
  (June 28, 2007)
• Q1-2007 - Period Ended January 31, 2007
  (April 3, 2007)
• Immunotec Inc. to Commence Trading on the TSX Venture Exchange
  (January 23, 2007)